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Metalloproteinases are secreted in response to a variety of inflammatory mediators and inhibited by tissue inhibitors of
matrixmetalloproteinases (TIMPs). Two members of these families, MMP-9 and TIMP-1, were differentially expressed depending
on clinical parameters in a previous genomewide mRNA analysis. The aim of this paper was now to evaluate the posttraumatic
serum levels and the time course of both proteins depending on distinct clinical parameters. 60 multiple traumatized patients
(ISS > 16) were included. Blood samples were drawn on admission and 6 h, 12 h, 24 h, 48 h, and 72 h after trauma. Serum levels
were quantified by ELISA. MMP-9 levels significantly decreased in the early posttraumatic period (P < 0.05) whereas TIMP-1
levels significantly increased in all patients (P < 0.05). MMP-9 and TIMP-1 serum concentration kinetics became manifest in
an inversely proportional balance. Furthermore, MMP-9 presented a stronger decrease in patients with severe trauma and non-
survivors in contrast to minor traumatized patients (ISS ≤ 33) and survivors, initially after trauma.
1. Introduction
Posttraumatic immune activation and dysfunction in form
of systemic inflammation response syndrome (SIRS), subse-
quent multiple organ dysfunction syndrome (MODS), and
multiple-organ failure (MOF) still remains a leading cause of
late posttraumatic morbidity and mortality [1]. MOF exerts
a profound influence on patient outcome, as it occurs in one-
fourth of all patients suffering from blunt multiple injuries
and accounts for 27.5% of death among trauma patients [2].
Previous genomewide studies have linked specific mRNA
expression patterns in monocytes with adverse outcome.
Among these differentially expressed genes that were signif-
icantly connected to distinct clinical parameters like injury
severity or outcome, matrix metalloproteinase-9 (MMP-
9) and its specific tissue inhibitor-1 (TIMP-1) could be
identified to play an important role in trauma patients in the
early posttraumatic period [3].
MMP-9 is part of the matrix metalloproteinase (MMPs)
family presenting a group of genetically distinct, but struc-
turally related zinc-containing proteolytic enzymes. Collec-
tively, MMPs play a central role in tissue remodeling of
extracellular matrix (ECM) being capable of degrading all
kinds of matrix components. Participating in ECM degrada-
tion they are involved in many biological processes such as
embryogenesis, angiogenesis, and wound healing [4]. They
are secreted as nonactive proenzymes in response to a variety
of inflammatory mediators and they are inhibited in vivo by
TIMPs [5]. Under physiological conditions MMP activities
are precisely regulated at several levels like transcription or
precursor zymogen activation and inhibition by their specific
endogenous inhibitors.
MMP-9 (92 kDa gelatinase) is a type IV collagenase
implicated in various aspects of inflammation including
accumulation of inflammatory cells, healing of tissue injury,
and remodeling processes. Specifically, it has been shown
2 Mediators of Inflammation
to mediate vascular leakage and to initiate the migration of
inflammatory cells inducing wound repair.
Furthermore, it is stored in the tertiary granules of
polymorphonuclear leucocytes, which are key effectors in
acute inflammatory diseases. Various cell lines such as
keratinocytes, eosinophils, neutrophils, and macrophages
can also express MMP-9 [6].
TIMP-1 works as a natural inhibitor of MMP-9 and is
found in most tissues and body fluids. By inhibiting MMPs
activities, TIMPs are involved in tissue remodeling and
regulation of ECM metabolism. The TIMP family consists of
four members sharing important structural features as well
as the ability of MMP inhibition. Under normal physiological
conditions, TIMPs bind MMPs in a 1 : 1 stoichiometry [4].
Consequently, a loss of activity control may result in a
variety of diseases such as arthritis, cancer, arteriosclerosis,
and fibrosis. Thus, the balance of MMP and TIMP activities
plays the pivotal role in both physiological and pathological
events [4].
Neither MMPs nor TIMPs have been described in
patients suffering from multiple major trauma and subse-
quent posttraumatic immune system alterations.
In dependence on the persuasive results of a serial
screening analysis of monocyte mRNA expression patterns
after blunt multiple injuries , main intention of this
investigation was the try to reproduce the MMP-9 and
TIMP-1 transcriptional profiles of an immune cell fraction
(monocytes) in serum samples of major trauma patients and
their potential relationship to distinct clinical parameters.
2. Patients and Methods
In this study, performed at a Level I trauma center according
to Good Clinical Practice (GCP), 60 adult patients (age > 18
years) presenting with multiple injuries and Injury Severity
Score (ISS) of greater than 16 points were included. Patients
were enrolled if the emergency department was reached
within 90 minutes after the traumatic event.
Signed informed consent was obtained from each patient
or their legal representatives over the course of time. Ethical
Committee Permission was obtained from the Ludwig-
Maximilians University, Munich, Germany (reference num-
ber: 012/00). Patients who did not survive the first 24 hours
after trauma were excluded.
After initial resuscitation and/or primary surgical inter-
vention according to standard of care, patients were admitted
to intensive care unit.
Retrospectively, patients were distributed to different
groups in regard to the two following clinical parameters:
injury severity assessed by ISS according to AIS98 and
outcome expressed by the survival of 90 days after trauma.
Serum samples were collected on admission (0 h), 6 h,
12 h, 24 h, 48 h, and 72 h after trauma. Afterwards they were
stored at −80◦C.
Protein concentrations were quantified by enzyme
linked immunosorbent assay (ELISA; Human-MMP-9 and
Human-TIMP-1 ELISA, Bender MedSystems GmbH).
For the analysis of MMP-9 and TIMP-1 protein levels in
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Figure 1: Significant decrease of mean MMP-9 serum levels in the
early posttraumatic period in comparison to initial mean MMP-9
serum concentrations at 0 h after the traumatic event. Data were
analyzed by Mann-Whitney Rank Sum test and presented by mean
± standard error of the mean (∗P < 0.05).
MMP-9 and 1 : 1000 to 1 : 5000 for TIMP-1 were required to
minimize the numbers of non evaluable results.
Resulting data was statistically analyzed using Mann-
Whitney Rank Sum Test (SigmaStat/SigmaPlot). A P value
of P < 0.05 was considered significant.
3. Results
3.1. Patient Collective and Clinical Data. Altogether 60
patients fulfilled the entry criteria and were included into the
study. Patients who did not reach the emergency department
within 90 minutes after trauma, patients who were younger
than 18 years, and patients who were pregnant or under
guardianship were excluded.
There were 42 male and 18 female major trauma patients
(mean age: 45 years; range: 18 to 93 years).
Patients were separated into different groups according
to injury severity and outcome. Injury severity was coded
according to ISS. We separated the patient collective into two
groups regarding the severity of trauma; that is, we used a
cut-off value of 33 points (group 1a: ISS ≤ 33, n = 33;
group 1b: ISS > 33, n = 27). Median ISS in all patients
was 33 (SD 11; range: 17 to 66). Median ISS of group 1a
was 27 points (SD 5); median ISS of group 1b was 50 points
(SD 22). Outcome was defined as a survival of 90 days after
trauma. Six patients deceased during this time frame (group
2a: survivors, n = 54; group 2b: non-survivors, n = 6).
Six patients did not survive the traumatic event (mean
age of non-survivors: 54 years; range: 37–93 years).
3.2. Serum Protein Concentrations
3.2.1. Time Course. Mean serum levels of MMP-9 and TIMP-
1 were detected by immunosorbent assay in a multiple-
trauma patient collective in the early posttraumatic period.
Figure 1 shows MMP-9 concentration in ng/mL during








n = 60 (all patients)
ISS 16–75






















Time of blood withdrawal (h)
P < 0.05
Figure 2: Significant increase of mean TIMP-1 serum concentra-
tion levels 6 h–72 h after the traumatic event compared to initial
mean TIMP-1 serum level at 0 h after trauma. Data were analyzed by
Mann-Whitney Rank Sum test and presented by mean ± standard
error of the mean (∗P < 0.05).
the time after trauma; Figure 2 demonstrates TIMP-1
concentration in ng/mL over the time.
MMP-9 reached a high concentration level in all inves-
tigated patients initially after trauma at the time point of
0 h. Afterwards, mean serum levels of MMP-9 decreased
significantly over the posttraumatic time period (6 h–72 h)
compared to serum concentration detected directly after
trauma (0 h).
In contrast to that, TIMP-1 started with low serum
concentration, which was continuously increasing during
this observation period (Figure 2). Mean serum levels of
TIMP-1 significantly increased during the observed time
period compared to the initial serum level (0 h).
Regarding the characteristics of MMP-9 and TIMP-1
serum levels, Figure 3 combined time course of MMP-9
and its specific inhibitor TIMP-1 during the observed time
period of 72 h after trauma. Both proteins demonstrated a
significant universal concentration pattern in all investigated
patients after severe injury, as MMP-9 showed a significant
downregulation whereas its physiological inhibitor TIMP-
1 presented a significant upregulation in the posttraumatic
period. This study’s results show a specific posttraumatic
serum concentration kinetics expressed by an inversely
proportional balance of MMP-9 and TIMP-1 in the early
time frame after multiple injuries.
3.2.2. ISS. Patients of group 1b presenting with an ISS
greater than 33 points showed a remarkable lower mean
MMP-9 serum concentration level initially (0 h) and in
the following 12 h after major injury than patients of
group 1a representing a collective of patients suffering from
moderate injury with an ISS between 16 and 33 points
(Figure 4). Concerning the following time points, mean
MMP-9 serum concentrations of both groups decreased
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Figure 3: Significant inversely proportional concentration kinetics
of MMP-9 and its specific inhibitor TIMP-1 during the observed
posttraumatic time period of 72 h. The blue line indicates the
connection of all measured time points concerning the significant
decrease of MMP-9 serum concentration whereas the red one
indicates the connection of all measured time points regarding the


























Group 1a: ISS 16–33 (n = 33)
Group 1b: ISS >33 (n = 27)
Time of blood withdrawal (h)
Figure 4: There is a lower serum MMP-9 activity in patients
presenting with an ISS > 33 points in contrast to those with an
ISS ≤ 33 regarding the first 12 h after trauma. Concerning the other
points of time, there is no further remarkable significant difference
between group 1a and 1b. Data were analyzed by Mann-Whitney
Rank Sum test and presented by mean± standard error of the mean.
Mean TIMP-1 serum concentration levels of both groups
did not distinguish significantly (Figure 5). TIMP-1 concen-
tration levels increased in the observed time period of 72 h
after trauma in group 1a and 1b without notable difference.
3.2.3. Outcome. Mean MMP-9 serum levels of patients
who did not survive the traumatic event (group 2b) dur-
ing an observation period of 90 days were compared to
those who survived (group 2a) in Figure 6. Remarkably,


























Group 1a: ISS 16–33 (n = 33)
Time of blood withdrawal (h)
Group 1b: ISS > 33 (n = 27)
Figure 5: Patients after major trauma (ISS > 33) and patients after
moderate injury (ISS ≤ 33) showed nearly equal mean serum levels
of TIMP-1 in the early posttraumatic period over 72 hours. There
were no significant differences found between these two groups.
Data were analyzed by Mann-Whitney Rank Sum test and presented



























Group 2a: survivors (>90-day survival)
Time of blood withdrawal (h)
Figure 6: Mean MMP-9 serum levels were remarkably lower in
non-survivors (group 2b) than those in survivors, especially within
the 24 h after the traumatic event. Data were analyzed by Mann-
Whitney Rank Sum test and presented by mean ± standard error of
the mean.
MMP-9 revealed considerable lower mean serum levels in
non-survivors (group 2b) than in survivors (group 2a)
immediately after multiple major injuries within the first
24 h after the traumatic event (Figure 6). In the subsequent
time interval, there were no significant differences between
the two groups. All in all, mean MMP-9 serum levels of
patients who did not survive the posttraumatic 90-day time
frame revealed lower serum protein concentrations than
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Group 2a: survivors (>90-day survival)
Figure 7: Mean TIMP-1 serum levels were lower in non-survivors
(group 2b) than those in survivors (group 2a) within the first 24 h
after multiple major injuries. 48 h and 72 h after trauma, mean
TIMP-1 serum levels of non-survivors were higher than mean
protein levels of patients who survived 90-days after the traumatic
event. Data were analyzed by Mann-Whitney Rank Sum test and
presented by mean ± standard error of the mean.
In Figure 7, mean TIMP-1 serum levels of survivors
(group 2a) and non-survivors (group 2b) are illustrated.
Observing the first 24 hours (0 h–24 h), mean TIMP-1 serum
levels of non-survivors are lowered in comparison to mean
serum TIMP-1 levels of survivors. Regarding TIMP-1 serum
levels at the moment of 48 h and 72 h, patients who did not
survive after trauma expressed definite higher mean TIMP-1
serum levels.
4. Discussion
A precedent serial, sequential oligonucleotide microarray
analysis of initial posttraumatic monocyte messenger RNA
could evaluate differential expression profiles in patients
suffering from multiple injuries. Thereby, specific gene
expression profiles have been identified to be significantly
associated with important clinical parameters like injury
severity and outcome [3].
Two of those identified eligible genes that were differen-
tially expressed according to clinical parameters code for the
two proteins were investigated in this study: MMP-9 and its
specific endogenous inhibitor TIMP-1.
Furthermore, matrix metalloproteinases are regarded
to be key role molecules in inflammation [7], as they
are involved in pathophysiological remodeling of the vas-
cular wall [8]. The aforementioned results of a previous
genomewide mRNA analysis on the one hand and the
gained prominence of MMPs as key role effectors in tissue
turnover, inflammation, and several diseases on the other
hand generated the intention to examine serum MMP-9 and
TIMP-1 kinetics, to evaluate their balance and to identify
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their outcome clarifying potential in patients after multiple
major injuries in the early posttraumatic period.
Consequently, the primary aim of this study was to
evaluate the balance of these proteins and to reproduce the
outcome clarifying monocyte mRNA signature in serum
samples of multiple injured patients.
In this context, serum level alterations of MMP-9 and
TIMP-1 depending on clinical outcome parameters could
have been the answer to early identify patients who are at risk
to develop severe posttraumatic complications in response
to their posttraumatic immune dysfunction leading to an
unfavorable outcome.
Especially, since a genomewide mRNA analysis is particu-
larly expensive, time-consuming, and restricted in terms of a
widely spread availability, altered outcome predicting serum
levels in multiple trauma patients could offer an instant and
easily performable chance to receive an individual view on
the immune status of each single patient and thereby evaluate
the individual risk of posttraumatic morbidity and mortality.
4.1. Protein Serum Levels
4.1.1. Time Course and Balance. The main and most impor-
tant result of this study is the identification of the convincing
universal concentration pattern of MMP-9 and TIMP-1 in
all investigated patients in the early posttraumatic period.
For the first time, this study’s results can state a significant
decrease of mean MMP-9 serum levels in the first 72 h
after trauma and simultaneously demonstrate a significant
increase of its specific inhibitor TIMP-1 in serum of multiple
traumatized patients immediately after the traumatic event.
Both proteins state an inversely proportional balance after
major injury, as it has not been evaluated in any other study
so far.
Neither MMP-9 nor TIMP-1 levels have yet been exam-
ined in patients suffering from blunt multiple injuries.
However, both proteins have built the basic of a multiplicity
of studies but have never been described in context of
multiple traumas. MMP-9 serum concentration levels have
been described in the context of several diseases such as
multiple sclerosis [9], coronary artery disease [10], multiple
myeloma [11, 12], and chronic lymphocytic leukemia [13,
14]. TIMP-1 serum concentration levels have been examined
in patients suffering from several types of cancer such as
colorectal cancer [15] and lung cancer [16], and also in terms
of acute disseminated encephalitis [17] or liver fibrosis [18].
Regarding the results of this current study, MMP-9 and
TIMP-1 present a characteristic concentration pattern and
contemporaneously a functional imbalance in patients after
multiple injuries, since the concentration kinetics became
manifest in an inversely proportional posttraumatic time
course. In regard to ISS and MOF, our results demonstrate
strong changes of MMP-9 concentration levels, especially
in severely injured patients (ISS > 33) and non-survivors
initially after trauma within the first 24 h after trauma. This
initial downregulation of MMP-9 in these two groups may be
understood as an answer to the severity of trauma, due to the
fact that it implicates nearly a loss of MMP-9 serum concen-
tration and in this context a loss of remodeling potential.
There might be different conceivable explanations for
these phenomena. In healthy subjects, MMP- 9 is cosecreted
with TIMP-1 in 1 : 1 stoichiometry. TIMPs are specific
inhibitors of MMPs whereupon TIMPs 1–4 can inhibit all
MMPs. TIMPs inhibit all MMPs tested so far, except that
TIMP-1 fails to inhibit MT1-MMP [19].
Under pathological conditions, which are associated with
an imbalance of MMP activities, changes of TIMP levels seem
to play an important role as they directly influence the level
of MMP activity [4].
Thus, in patients with multiple major injuries, there
is a significant overproduction of TIMP-1 over MMP-9
as investigated in this study. The functional consequence
of the TIMP-1/MMP-9 imbalance in multiple traumatized
patients is impressive and may in this context be under-
stood as a generalized downregulation of MMP-9 activity
and consequently its remodeling potential induced by the
overexpression of TIMP-1 in the very early posttraumatic
period.
Remodeling is defined as to “model again or reconstruct”.
As already mentioned, the main role of MMPs remains
ECM and basement membrane breakdown in the context
of tissue remodeling and angiogenesis, whereas the key
role of TIMPs is the maintenance of the essential balance
between deposition and degradation of ECM by their
function as endogenous inhibitors of MMP activities. The
major intention of wound healing is the restoration of a
functional connective tissue. Additionally, this regenerative
process depends upon the accumulation and deposition of
ECM molecules and besides the remodeling of ECM by
MMPs [19].
In accordance with these physiological mechanisms, this
study’s result may be construed in the following way. The
significant decrease of MMP-9 in the early posttraumatic
period induced by a coincidental, significant overproduction
of its physiological inhibitor in all patients after severe
injury might reflect the organism’s reaction on the distinct
tissue injury and immune reaction caused by the traumatic
event. MMP-9 activity—if correlated with the “remodeling
potential”—has to be reduced significantly to cope with the
posttraumatic damage. In consequence, the severely injured
organism restricts the regenerative process depending upon
MMP activity. This can be understood as a “rescue” response
to the impact of trauma and the entailed overwhelming
posttraumatic immune alteration.
Nevertheless, these protein serum results depending
on injury severity and outcome could only demonstrate
tendencies and could not reproduce the highly significant
changes in monocyte mRNA expression patterns initially
after trauma in a genomewide analysis so far.
There are several suggestions in the literature about
monocytes playing a pivotal role in posttraumatic immune
alterations, as they are an important part of innate immune
system [20]. Hypothetically, the very early monocyte mRNA
expression changes cannot be found in serum, as MMP-
9 concentration changes once initiated in the intracellular
space have not been secreted into serum so far.
On the other hand, monocytes only represent a small
cell fraction of the cellular blood ingredients (2–8% of all
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leucocytes), in comparison to the multiple ways of secretion,
activation, and inhibition seen in patients’ serum. This
may explain why the distinct significance in the monocyte
signature cannot be clearly reproduced in serum.
4.1.2. Blood Sampling. The determination of matrix met-
alloproteinases in peripheral blood as a noninvasive and
easily performable possibility of diagnosis and monitoring
of several diseases has already been recommended, since
MMP activities on cellular level are reliably reflected in body
fluids such as serum and plasma [21]. Peripheral blood
contains several forms of MMPs. It can be found in soluble
constitutive form in plasma and in form of intracellular
zymogenes in platelets and leukocytes, which is followed by a
release of proteinase into the circulation particularly in terms
of a disease [22]. Thus, changes of MMP activity in serum
measurements have been detected in several diseases and
can therefore act as an indicator for pertinent intracellular
protease activity [23].
However, discrepancies in MMP concentration lev-
els depending on blood sampling procedure have been
described in several studies [24]. Possible preanalytical errors
of TIMP and MMP measurement in peripheral blood have
been a matter of debate. In this context, elevated serum
MMP levels have been described as serum levels of matrix
metalloproteinases are likely influenced by MMP release
following degranulation of leukocytes and platelets during
the ex vivo blood clotting [25].
Nevertheless, most studies work with serum as medium
to evaluate MMP concentration levels, because serum rep-
resents a likely affordable and reliable blood sampling pro-
cedure to easily investigate MMP and TIMP concentration
levels in patients suffering from several diseases. Serum con-
centrations have been detected in terms of neurodegenerative
diseases, cardiovascular diseases, or malignant proliferation,
for example [23].
4.1.3. Patient Collective and Clinical Data. In reference to
mean age (45 years) and distribution between the sexes of
nearly 2 : 1 (men : women), this study’s patient collective is
well comparable to patient collectives described in assim-
ilable European and American studies of multiple injured
patients [26].
In accordance with the aforementioned entry criteria,
only patients who reached the emergency department within
90 minutes after trauma were included in this study. In
regard to other research groups’ investigations on circulating
neutrophils, the chosen blood-sampling time points in this
study were set in the following way: on admission, which
means within 90 minutes after trauma, and again 6 h, 12 h,
24, 48 h, and 72 h after the traumatic event [27].
It is well known that particularly the very early post-
traumatic period sets the course for the appearance of
a later multiple-organ failure [28]. Furthermore, trauma-
induced alterations in the innate immune response lead to
a subsequent immune cell-regulated defense reaction ending
in hyperinflammation, immunoparalysis, or a combination
of both, particularly in the early posttraumatic period
[29]; therefore, a serial analysis of inflammation parameters
including this vulnerable posttraumatic time frame after
multiple major injuries is indispensable.
The definition of injury severity and the development of
multiple-organ failure as well as setting the respective cut-off
points in order to build dichotomous clinical groups requires
the use of scoring systems as it was done in our study using
ISS.
For this reason, serum samples were only collected if
patients suffered from blunt multiple injuries with an injury
severity greater than 16 points, as assessed by the ISS-
Scoring System, the standard method of rating severity of
injury [30]. In regard to injury severity, a cut-off level had
to be defined to differentiate between minor and major
traumatized patients. That is why we depended on building
two opposite groups for our analysis, as the number of our
investigated patient collective was too few to calculate a
reliable multiple regressive analyses respecting the particular
ISS count in every single patient. For these biostatistical
reasons, we switched to the analysis of two dichotomous
groups. Concerning injury severity, a cut-off of 33 points was
appointed in this study to distinguish between major and
minor traumatized patients, for an ISS of 33 points was the
median ISS in our patient collective. This might be a limiting
factor of this study. However, there is no definitive ISS cut-off
level differentiating between minor and major traumatized
patients published in literature so far.
In contrast to ISS mentioned previously, outcome is a
simple and straightforward clinical criterion as it is just
defined as a survival of more than 90 days after trauma.
The evident advantage of this clinical criterion is the
clear definition whereas its main limitation might be the
inhomogeneity exhibited in both groups (survivors, non-
survivors) as neither the cause of death nor the variety of
posttraumatic individual complications after surviving the
initial trauma is attended.
5. Conclusions
Regarding the time course of significantly decreasing MMP-
9 and significantly increasing TIMP-1 serum levels, we can
state a universal concentration pattern after blunt multiple
injuries in all investigated patients. Both proteins show a
typical inversely proportional serum concentration kinetics
in the first 72 h after trauma.
Furthermore, the very early posttraumatic period is
characterized by a remarkable decrease of MMP-9 serum
concentration initially after trauma in patients with a major
injury (ISS> 33) and those who did not survive the traumatic
event in contrast to patients with moderate injury and
those who survived. This might be due to the fact that the
remodeling potential of MMP-9 is strongly downregulated
in patients suffering from severe traumatic injury as well as
in non-survivors.
The inversely proportional balance between MMP-9 and
its endogenous inhibitor TIMP-1 and the decrease of MMP
activity in severely injured (ISS > 33) and non-survivors
suggest a potentially new mechanism of posttraumatic
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immune system dysbalance and SIRS/MOF precondition
following multiple injuries.
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